1.
Introduction Radium-223 is a first-in-class targeted alpha therapy for castration-resistant prostate cancer (CRPC) and symptomatic bone metastases with minimal myelosuppressive effects [1, 2] . The relatively large size of alpha particles, coupled with the high linear energy transfer of emitted particles, results in a short path length and localized area of cell destruction (<100 mm; 2-10 cell diameters), inducing predominantly nonrepairable double-stranded DNA breaks [3] . Unlike beta particles emitted from strontium-89 and samarium-153, the much shorter range of alpha particles spares hematopoietic bone marrow and produces a more tolerable safety profile.
Agents approved for use in patients with CRPC have been associated with significant toxicities. These include the taxanes docetaxel and cabazitaxel, which have a range of chemotherapy-related effects [4] [5] [6] . Beta-emitting radiopharmaceuticals such as strontium-89 and samarium-153, used for pain palliation in CRPC patients with bone metastases, are associated with significant myelosuppression [1, 2, 7, 8] .
In the phase 3 Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 plus best standard of care (BSoC), versus placebo plus BSoC, prolonged median overall survival by 3.6 mo (14.9 vs 11.3 mo; p < 0.001) [9] . Additionally, radium-223 was well tolerated and associated with a low incidence of grade 3 or 4 myelosuppression (radium-223 vs placebo: anemia, 13% vs 13%; neutropenia, 2% vs 1%; and thrombocytopenia, 7% vs 2%). Based on ALSYMPCA efficacy and safety results, radium-223 was approved for treatment of patients with CRPC and symptomatic bone metastases and no known visceral metastases.
Although these radium-223 safety data are reassuring, long-term safety monitoring of radium-223 is essential to provide a comprehensive safety profile, including posttreatment adverse event (AE) data, and to afford clinicians a higher level of confidence in radium-223 overall safety. This article reports radium-223 final safety data from ALSYMPCA trial. Data presented are updated from previously reported safety results [9] , with additional long-term safety from 12 wk after each patient's last injection up to 3 yr after their first injection.
2.
Patients and methods
Patients and study design
Complete ALSYMPCA study methods were previously reported [9, 10] Fig. 1 ). BSoC was defined as routine care provided at each center and included external beam radiation therapy for bone pain as indicated. Randomization was done with an interactive voice response system, taking into account trial stratification factors. After study unblinding, placebo patients who still met the eligibility criteria were offered radium-223 (placebo crossover patients).
The long-term safety follow-up period started 12 wk after the last study-drug injection (end of treatment) and continued until 3 yr from the first study-drug injection. During follow-up, patients were evaluated every 2 mo for 6 mo, then every 4 mo for up to 3 yr ( Fig. 1 ).
The primary ALSYMPCA end point was overall survival; secondary end points included acute and long-term safety.
Study assessments
Safety assessments included AEs, graded according to Common Deaths were considered to be related (probably or possibly) or unrelated to study treatment, as judged by the investigator.
Statistical analyses
Statistical methods used in ALSYMPCA study have been described (July 2011 database lock) [9] . Data presented here include updated safety data separately to account for all patients who received radium-223 treatment and to evaluate whether the few placebo crossover patients affect the overall safety findings. Separate safety analyses were performed on the patient subset that entered the long-term safety follow-up period. Demographics, disposition, and safety variables were summarized descriptively. Data were analyzed using SAS Version 9.1.3.
Results

Patients
The safety population included 901 patients (600 radium-223 and 301 placebo) who received one or more study-drug injections (Fig. 2) . Baseline demographics and clinical characteristics were well balanced across treatment groups ( Table 1 ). Median follow-up time from the first injection up to 3 yr was 13 mo (range, 0-36 mo) for radium-223 patients and 9 mo (range, 0-36 mo) for placebo patients.
Updated safety during treatment period
Overall in this updated analysis of the original ALSYMPCA study publication [9] , 564/600 (94%) radium-223 and 292/301 (97%) placebo patients had one or more TEAEs during the treatment period up to 12 wk following the last injection (Table 2 ). Radium-223 was associated with a low incidence of myelosuppression; grade 3/4 hematologic TEAEs in radium-223 and placebo groups were anemia in 13% and 13%, neutropenia in 2% and 1%, and thrombocytopenia in 7% and 2%, respectively. Grade 5 TEAEs occurred in 98/600 (16%) radium-223 and 68/301 (23%) placebo patients ( both treatment groups. In the radium-223 group, one patient had carcinoma of unknown origin, one had squamous cell carcinoma, one had intestinal adenocarcinoma, and two had skin neoplasms (types unknown). In the placebo group, one patient had neoplasm of unknown origin and one had gastric cancer.
Patients who entered long-term safety follow-up
Of 901 patients in the ALSYMPCA safety population, 572 (405 radium-223 and 167 placebo) entered the designated 3-yr long-term safety follow-up period. Baseline demographic and clinical characteristics of those patients were generally similar across treatment groups ( 
3.4.
Safety during long-term safety follow-up
Post-treatment treatment-related AEs in patients who entered 3-yr long-term safety follow-up are presented in Table 4 . Overall incidence of myelosuppression was 3%; nonhematologic AEs were 1%. There were no reports of AML or MDS. Aplastic anemia based on bone marrow biopsy was reported in one radium-223 patient at follow-up visits 5 and 6 (16 and 20 mo from the last injection) and was considered by the investigator to be probably related to study drug. No new primary bone cancer was reported. In addition to the secondary malignancies reported during treatment, a number of secondary malignancies were reported during long-term follow-up and considered not related to study drug. In the radium-223 group, one patient had bladder cancer reported at follow-up visit 1 (3 mo after the last injection) and one had lymph node metastases of unknown origin reported at follow-up visit 6 (20 mo after the last injection). In the placebo group, one patient had squamous cell carcinoma of the left hand reported at follow-up visit 2 (6 mo after the last injection), one had adenocarcinoma of the rectum and adenocarcinoma of the sigmoid colon reported at follow-up visit 4 (12 mo after the last injection), and one had skin cancer (type unknown) reported at followup visits 7 and 8 (24 and 28 mo after the last injection). In the placebo crossover group, one patient had squamous cell carcinoma of the skin reported at follow-up visit 1 (3 mo after the last injection) and one had meningioma reported at follow-up visit 2 (6 mo after the last injection).
Cumulative incidence rates for hematologic and nonhematologic AEs of interest and for secondary malignancies were low (Supplementary Table 5 and Supplementary  Fig. 1A-C ).
3.5.
Deaths during study (treatment and safety follow-up periods)
During the treatment period, 111/600 (19%) radium-223 and 78/301 (26%) placebo patients died (Supplementary Table 6 ). Deaths of two radium-223 patients were considered possibly related to study treatment: one patient who received two injections died of possible myocardial infarction or bowel ischemia 8 wk after the first injection; one patient who received one injection died of general deterioration of health with multiple organ failure within 4 wk after the first injection. During long-term safety follow-up, a higher percentage of placebo patients than radium-223 patients died or dropped out (Supplementary Table 3 ). Deaths of two radium-223 patients were considered by the investigator to be related to study treatment. Both patients received all 
Discussion
Consistent with previous analyses [9, [12] [13] [14] , this updated final long-term safety follow-up analysis from ALSYMPCA trial in CRPC patients with symptomatic bone metastases showed that radium-223 continued to be well tolerated, with a low incidence of myelosuppression, long-term preservation of hematopoietic function, and no new safety signals.
Radium-223 compares well in safety with the hormonal therapies abiraterone and enzalutamide [15] [16] [17] [18] [19] , but is unlike the cytotoxic chemotherapies, in which myelosuppression is the most frequent AE [20, 21] . In the phase 3 TROPIC study, treatment with cabazitaxel was associated with significant myelosuppression (all grades neutropenia [94%], leukopenia [96%], anemia [97%], and thrombocytopenia [47%]) with relatively high rates of febrile neutropenia (8%) [4] . Furthermore, neutropenia frequently occurs in docetaxel-treated patients [20] . Radium-223 is also distinct from the beta-emitting radiopharmaceuticals, which are associated with significant hematologic AEs (mainly leukopenia and thrombocytopenia) [22, 23] .
In this 3-yr long-term safety analysis, secondary malignancies occurred in four radium-223 patients and three placebo patients. The percentages of radium-223 and placebo patients who received anticancer medications and radiotherapies during follow-up were generally similar. A study limitation is that assessment of long-term radium-223 safety may be difficult given that many participants were treated with other anticancer therapies in combination with radium-223 during the follow-up period. Secondary malignancies induced by cancer therapies are of clinical interest, as they are a cause of morbidity and mortality in long-term cancer patients. Although secondary malignancies are uncommon, they can be a serious consequence of radiotherapy for cancer treatment [24] . None of the secondary malignancies were considered related to radium-223, and no new primary bone cancer was reported; however, another study limitation was that the follow-up was limited to 3 yr, which is a relatively short time to assess the number of treatment-induced cancers, including hematologic malignancies. Additional studies with longer follow-up times are necessary to more accurately assess the long-term safety of radium-223. Another study limitation was that AEs were reported during follow-up only if considered by the investigator to be treatment related and may therefore be under-reported. Enrollment is currently ongoing in an international, prospective, observational, single-arm study (Radium-223 Alpha Emitter Agent in Safety Study in mCRPC Population for Long-Term Evaluation) aiming to assess the incidence of second primary malignancies in CRPC patients with bone metastases who are receiving radium-223 in routine clinical practice. Patients will be followed until 7 yr after the last radium-223 dose (NCT02141438). Of the patients who entered long-term safety follow-up, a higher percentage of radium-223 patients compared with placebo patients were alive at the end of the 3-yr period (14% vs 7%). These results, together with the unique mechanism of action and favorable safety profile during treatment and follow-up periods, make radium-223 an important treatment option, with potential for sequencing and combination with other agents for CRPC patients.
The current safety profile of radium-223 is based on a treatment course of six injections (50 kBq/kg [55 kBq/kg following the NIST update]) [11] given at 4-wk intervals. Studies are ongoing with higher-dose or extended-dose radium-223 regimens (NCT02023697) and combination with other agents (NCT02034552 [radium-223 + abiraterone or enzalutamide], NCT02043678 [radium-223 + abiraterone + prednisone/prednisolone], NCT01106353 [radium-223 + docetaxel]). Results from a phase 1/2 international, multicenter, prospective study in a highly selected population of patients with CRPC and bone metastases who were retreated with six additional radium-223 doses (NCT01934790) showed that retreatment with radium-223 was well tolerated, with minimal hematologic toxicity [25] . Results from these studies will further contribute to our understanding of the overall safety and efficacy of radium-223.
Conclusions
This updated final long-term safety follow-up ALSYMPCA analysis shows that radium-223 is well tolerated in CRPC patients with symptomatic bone metastases, with minimal nonhematologic AEs, a low incidence of myelosuppression with long-term preservation of hematopoietic function, and no new safety signals.
Future perspectives
The safety of radium-223 combined with the unique mechanism of action and prolongation of overall survival suggests the possibility of combining it with other agents. Additionally, earlier radium-223 use in patients with a low bone disease burden has the potential advantage of allowing patients to receive the recommended dosing regimen of six injections and to sequence this agent with subsequent therapies. Clinicians should consider using the most efficacious and safest agents early in treatment, thereby affording the possibility of allowing patients to better tolerate subsequent therapies and achieve maximum survival benefit. These updated ALSYMPCA safety data provide support for using radium-223 treatment earlier in the disease course, thus ensuring that patients achieve the full six injections of radium-223, the regimen associated with longer overall survival.
